By continuing to grow in response to the requirements of our clients, Creative Biolabs is dedicated to exploring novel and innovative technologies to offer the most comprehensive, integrated portfolio of cellular therapy products and solutions. We are proud to partner with our clients on the journey of bringing novel cellular therapies to market.
Antibody-Coupled T Cell Receptor (ACTR) Technology
ACTR consists of one extracellular domain, a transmembrane domain, co-stimulatory signaling domain and TCR signaling domain which is similar to CAR design. The specificity of ACTR compared with CAR is the extracellular domain which is derived from CD16, a receptor capable of binding to the Fc domain of different antibodies. The ACTR T cell can’t recognize tumor cells directly. While, once the tumor-targeting antibody is provided to bind to the surface of tumor cells, the ACTR T cell can recognize the tumor cells indirectly via the Fc domain of antibodies. This will enable the antibody-dependent cellular cytotoxicity (ADCC) for tumor cell killing.
Our Antibody-Coupled T Cell Receptor (ACTR) Platform
Advantages of ACTR Technology
Our scientists leverage the ACTR technology to create a universal T cell therapy that functions with a variety of tumor-targeting antibodies. Furthermore, another intrinsic advantage is the activity of ACTR T cell therapy can be controlled by antibody dosing. An ideal therapeutic window can be potentially defined by increasing or decreasing the amount of tumor-targeting antibody. This enables maximizing the level of cancer-killing with minimizing side effects. The unique advantages of this technology will increase the efficiency and value of your T cell therapy, and maximize the success of your project.
To help our clients develop safe and effective T cell therapies, Creative Biolabs is continuously exploring novel technologies including ACTR, Nanoparticle, VST etc. Our ACTR technology provides a broadly applicable combination treatment for a wide range of cancer types. Furthermore, we are committed to exploring modifications to ACTR technology for better applications. If you are interested in our ACTR technology, please feel free to contact us for closer communication to learn how we can be involved in your project. Separate services or integrated end-to-end solutions are all welcomed.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE